Article Text

Download PDFPDF

Newly developed pseudogout arthritis after therapy with MAGE-A4 directed TCR T cells responded to treatment with tocilizumab
  1. Sang T. Kim1,
  2. Jean Tayar1,
  3. Siqing Fu2,
  4. Danxia Ke2,
  5. Elliot Norry3,
  6. Amy Sun3,
  7. Juli Miller3 and
  8. David S. Hong2
  1. 1 General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
  2. 2 Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
  3. 3 Adaptimmune Therapeutics plc, Philadelphia, Pennsylvania, USA
  1. Correspondence to Dr Sang T. Kim; stkim{at}


With durable cancer responses, genetically modified cell therapies are being implemented in various cancers. However, these immune effector cell therapies can cause toxicities, including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Pseudogout arthritis is an inflammatory arthritis induced by deposition of calcium pyrophosphate dihydrate crystals. Here, we report a case of pseudogout arthritis in a patient treated with MAGE-A4 directed T cell receptor T cells, for fallopian tube cancer. The patient developed CRS and ICANS 7 days after infusion of the T cells. Concurrently, the patient newly developed sudden onset of left knee arthritis. Synovial fluid analyses revealed the presence of calcium pyrophosphate dihydrate crystal. Notably, the pseudogout arthritis was resolved with tocilizumab, which was administered for the treatment of CRS and ICANS. Immunoprofiling of the synovial fluid showed that the proportion of inflammatory interleukin 17 (IL-17)-producing CD4+ T (Th17) cells and amount of IL-6 were notably increased, suggesting a potential role of Th17 cells in pseudogout arthritis after T-cell therapy. To the best of our knowledge, this is the first reported case of pseudogout arthritis after cell therapy. Clinicians, especially hematologists, oncologists and rheumatologists, should be aware that pseudogout arthritis can be associated with CRS/ICANS.

  • autoimmunity
  • case reports
  • CD4-positive T-lymphocytes
  • translational medical research

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


Immune effector cell (IEC) therapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) therapies, have opened a new chapter in cancer therapeutics.1 Anti-CD19 CAR-T cell therapies (such as axicabtagene ciloleucel, tisagenlecleucel, brexucabtagene autoleucel, and lisocabtagene maraleucel) have shown clinical benefits and have recently been approved by the U.S. Food and Drug Administration for diffuse large B cell lymphoma, mantle cell lymphoma, and acute lymphoblastic leukemia. However, IEC therapy can cause toxicities including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).1 CRS is the most common toxicity of IEC therapy, and its clinical manifestations include fever, tachycardia, hypotension, dyspnea, and organ dysfunctions. Inflammatory cytokines secreted from activated T cells and bystander immune cells including interleukin (IL)-6, interferon gamma (IFNγ), and granulocyte-macrophage colony stimulating factor (GM-CSF) are thought to play a critical role in CRS.2 ICANS is another toxicity of IEC therapy. Patients with ICANS have various neurologic symptoms including delirium, hallucination, cognitive dysfunction, and/or memory deficits, seizures, ataxia, and encephalopathy.1 The underlying pathogenesis of ICANS is elusive. Treatment for IEC therapy toxicities includes supportive care and immunosuppressants such as tocilizumab, an IL-6 receptor blocker).1 Of note, due to concerns of IEC suppression, steroids are frequently reserved as a second-line therapy for CRS refractory to tocilizumab.1 3 4

Pseudogout, induced by the deposition of calcium pyrophosphate dihydrate (CPPD) crystal, is an autoinflammatory disorder.5 The innate immune system and inflammasomes are known to play an essential role in its pathogenesis.5 Here, we report the first case of newly developed, crystal-proven pseudogout arthritis after infusion of MAGE A4 directed TCR T cells. The patient developed pseudogout arthritis along with CRS and ICANS. Interestingly, tocilizumab, which was used to treat the CRS and ICANS, also worked for the pseudogout arthritis. In parallel, we performed immunoprofiling of the synovial fluid obtained at the pseudogout flare.

Case presentation

The patient was a 78-year-old woman with a history of hypertension. The patient had been well until early 2015, when she started to have nausea and vomiting. Workup revealed high-grade serous carcinoma of the right fallopian tube. The patient underwent neo-adjuvant chemotherapy with carboplatin plus paclitaxel followed by total abdominal hysterectomy and bilateral salpingo-oophorectomy. The patient received adjuvant chemotherapy with carboplatin plus taxotere. However, 1 year later, the tumor recurred and the patient underwent chemotherapy with carboplatin plus doxorubicin. The tumor response was inadequate, so the patient enrolled in a clinical trial and received MAGE-A4 directed TCR T cells. Seven days after the infusion, the patient developed a fever (38.6°C), nausea, and difficulty writing and calculating. She also developed sudden-onset pain and swelling in her left knee. No similar episodes of joint pain and/or swelling had occurred in the past. Diagnostic arthrocentesis was performed. Synovial fluid analysis showed a white cell count within the inflammatory range (12 714/μL) and numerous intracellular and extracellular CPPD crystals. Gram stain and culture were negative. Serum IL-6 was elevated at 260 pg/mL (normal range: 0–5 pg/mL). Secondary causes of pseudogout arthritis, including hypothyroidism, hyperparathyroidism, hypomagenesemia, hypophosphatemia, and hemochromatosis,6 were ruled out either clinically or by laboratory tests (table 1). CT of the head was unremarkable, but brain MRI revealed hyperintensity on the posterior cerebral sulci. The patient was diagnosed with CRS and ICANS. The grade of CRS and ICANS were 1 and 2, respectively. For CRS and ICANS, the patient received 8 mg/kg of tocilizumab intravenously, and her symptoms, including arthritis, resolved over 3 days.

Table 1

Laboratory data

Materials and methods

Isolation of cells

After the diagnostic arthrocentesis, residual synovial fluid of the left knee was collected. Synovial fluid samples were incubated with 10 IU collagenase III (Sigma, Cat No: H3506) at 37 °C for 30 min. After incubation, the sample was centrifuged at 500G for 10 min and the synovial fluid supernatant was collected. The remaining cells were washed with phosphate-buffered saline (Gibco) and cryopreserved in the presence of 90% fetal bovine serum (Gibco, Cat No: 16140071) and 10% dimethyl sulfonoxide (Sigma, Cat No: D2650).

Flow cytometry

Cryopreserved synovial fluid cells were thawed, washed, and stained with flow cytometry antibodies. For intracellular cytokine staining, cells were stimulated for 4 hours in the presence of cell stimulation cocktail containing phorbol 12-myristate-13-acetate, ionomycin, and brefeldin A (Biolegend, Cat No: 423303). Subsequently, cells were stained to detect surface molecules, fixed (BD CytoFix/CytoPerm, Cat No: 51-2090KZ) and permeablized (BD PERM/Wash solution, Cat No: 51-2091KZ). After permeablization, the cells were stained to detect intracellular molecules. Flow cytometry data were acquired by BD LSR II FORTESSA X-20 and analyzed with FlowJo software (TreeStar, CA). Following antibodies were used for the flow cytometry; LIVE/DEAD Zombie Aqua (BioLegend), anti-CD19 PE (HIB19, BioLegend), anti-CD3 PerCP/Cyanine 5.5 (SK7, BioLegend), anti-TCR gamma/delta Brilliant Violet 421 (B1, BioLegend), anti-CD45RA Brilliant Violet 785 (HI100, BioLegend), anti-CD56 FITC (HCD56, BioLegend), anti-CD19 Brilliant Violet 785 (HIB19, BioLegend), anti-CCR7 PE-Cy7 (G043H7, BioLegend), anti-CD4 BUV395 (SK3, BD Horizon), anti-CD8 Alexa Fluor 700 (HIT8a, BioLegend), anti-CD25 FITC (BC96, BioLegend), anti-C-X-C chemokine receptor type 5 (CXCR5) APC (J25D4, BioLegend), anti-CD127 Alexa Fluor 700 (A019D5, BioLegend), anti-IL-4 Brilliant Violet 421 (MP4-25D2, BioLegend), anti-IL-21 PE (3A3-N2.1, BD Horizon), anti-IFNγ PE/Dazzle 594 (4S.B3, BioLegend), anti-IL-17A PE-Cy7 (BL168, BioLegend).

Enumeration of synovial immune cells

To enumerate major immune cell subsets, we adapted and modified the gating strategy which we previously published.7 We calculated proportions of CD4+ T cell subsets including CD45RA+ naïve, regulatory T cells (Tregs; CD25hi CD127lo), CXCR5 expressing follicular helper T cells, a distinct CD4+ T cell subset helping B cells,8 and CD45RA- CXCR5- effector cells. We also enumerated CD4+ T cells producing effector cytokines including IFNγ, IL-4, IL-17, and IL-21.

Cytokine measurement

The levels of IFNγ, tumor necrosis factor alpha, GM-CSF, IL-1β, IL-2, IL-4, IL-6, IL-10, IL-17A, IL-21, and IL-22 were measured by multiplex ELISA techniques using commercially available kits (U-Plex Th17 Combo 2, Meso Scale Discovery), according to the manufacturer’s instructions.


Flow cytometry revealed that myeloid cells were most dominant major immune cell subsets in the synovial fluid (94.6% within live single cells) (figure 1A,B). The effector memory population was increased within both CD4+ and CD8+ T cells, suggesting they may be involved in the pathogenesis of the pseudogout arthritis in our case (figure 1C).

Figure 1

Flow cytometry analysis of synovial immune cells at pseudogout arthritis flare. (A) Flow cytometry gating strategy of major immune cells. Temra, terminally differentiated T cells. (B) Percentage of major immune cell subsets within total live single cells. (C) Percentage of T cell subsets. (D) Percentage of CD4+ T cell subsets. Flow cytometry plots of CD4+ T cells and quantitative analysis. Gating of CD45RA and CXCR5 was made based on the expression of CD45RA and CXCR5 on anonymous tonsillar non-Tregs. (E) Percentage of cytokine-producing CD4+ T cells. Flow cytometry plots and quantitative analysis. (F) Hypothetical model of pseudogout arthritis associated with CRS/ICANS. Mϕ, macrophages; Nφ, neutrophils. CRS, cytokine release syndrome; CXCR5, C-X-C chemokine receptor type 5; FSC-A, forward scatter area; ICANS, immune effector cell-associated neurotoxicity syndrome; IFNγ, interferon-γ; IL-17, interleukin 17; NK, natural killer cells; NK T, NK T cells; SSC-A, side scatter area; TEM, effector memory T cells; TCM, central memory T cells; TN, naïve T cells; Treg, regulatory T cells.

Given the central role of CD4+ T cells in immune responses, we focused on CD4+ T cells (figure 1D,E). The most abundant CD4+ T cell subset was CXCR5- CD4+ effector T cells (54.5% within live CD4+ T cells) (figure 1D). Intracellular staining of CD4+ T cells showed predominance of IFNγ producing CD4+ T helper 1 (Th1) cells and IL-17 producing CD4+ T helper 17 (Th17) cells (49.0% and 22.6% within CD4+ T cells, respectively) (figure 1E). Multiplex analysis of the SF supernatant revealed the significant levels of IL-6, a key cytokines for Th17 cell differentiation, function, and plasticity (table 2).9

Table 2

Cytokine concentration in synovial fluid


To the best of our knowledge, this is the first report of a case of newly developed, crystal-proven, pseudogout arthritis associated with CRS/ICANS after cell therapy. Of note, the patient’s pseudogout flare was resolved with tocilizumab. Our clinical observation is particularly important as steroids, the first-line therapy for pseudogout arthritis, are frequently avoided for the treatment of IEC-associated toxicities due to their potential lymphocytolytic activity.1 3 4 10 Immunoprofile of synovial fluid revealed the dominance of Th1 and Th17 cells with abundant IL-6.

Innate immune cells, primarily neutrophils and macrophages, are pivotal in the pathogenesis of pseudogout arthritis. Macrophages identify and phagocytose CPPD crystals, activating Nod-like receptor protein inflammasomes, with subsequent secretion of IL-1β, a potent inflammatory cytokine.11 In CRS, inflammatory cytokines secreted from the CAR-T cells can activate bystander immune cells, including macrophages, monocytes, and dendritic cells, with subsequent production of IL-6.12 IL-6 is known to be important for the differentiation, function, and survival of Th17 cells, which are a subset of CD4+ T cells involved in many autoimmune diseases.8 9 Interestingly, the proportion of Th17 cells in the synovial fluid in our case was substantially higher than what has been previously reported in classical inflammatory arthritis.13 Thus, it is plausible that, in our case, inflammatory cytokines activated bystander macrophages, which secreted IL-6, thus contributing to Th17 differentiation, function, and survival. In turn, these Th17 cells enhanced recruitment of neutrophils to the site of the CPPD crystal deposition. Taken together, we speculate that in addition to IL-1β induced by the CPPD crystal, an IL-6-Th17-neutrophil axis played a critical role in the pathogenesis of CPPD arthritis in our patient. This hypothesis is supported by the clinical observation that the patient’s pseudogout arthritis was resolved completely with tocilizumab. We show our hypothesis graphically in the figure 1F.

This is the first case reporting pseudogout arthritis in a patient who developed CRS and ICANS after T cell therapy. Importantly, pseudogout arthritis of our patient was resolved with tocilizumab. Because IEC therapy is being increasingly used in various cancers, there may be an increased recognition of CPPD arthritis in patients undergoing IEC therapy, and clinicians, including hematologists, oncologists, and rheumatologists, should be aware that IEC might be associated with the development of arthritis. Immunophenotypic analyses in our case suggest the contribution of a feed-forward loop between macrophages, neutrophils, and Th17 cells in the joint inflammation. Comprehensive analyses of more cases and control samples are warranted to understand the underlying mechanisms of pseudogout arthritis and its potential association with IEC therapy.

Ethics statements

Ethics approval

Synovial fluid collection for the study was approved by an Institutional Review Board at The University of Texas MD Anderson Cancer Center (IRB #: PA16-0935). Consent to participate was obtained.



  • Contributors JT, SF and DSH. managed the case; STK. performed experiments, analyzed the data, and wrote the manuscript; DK, EN, AS and JM. analyzed and discussed the data; all authors reviewed and edited the manuscript.

  • Funding This study was supported by the University of Texas MD Anderson Cancer Center Division of Internal Medicine Bridge Fund (STK).

  • Competing interests EN, AS and JM are employees of Adaptimmune LLC and own stock in the company. DSH has research fundings from AbbVie, Adaptimmune, Adlai Nortye, Amgen, Astra-Zeneca, Bayer, Bristol Myers Squibb, Daiichi-Sankyo, Eisai, Eli Lilly, EMD Serono, Erasca, Fate Therapeutics, Genentech, Genmab, GlaxoSmithKline, Ignyta, Infinity, Kite, Kyowa, LOXO, Merck, MedImmune, Millenium, Mirati, miRNA, Molecular Templates, Mologen, Navier, NCI-CTEP, Novartis, Numab, Pfizer, Seattle Genetics, Takeda, Turning Point Therapeutics, Verstatem, and VM Oncology. DSH has supports for travel, accommodations, and expenses from AACR, Amgen, ASCO, Astra Zeneca, Bayer, Celgene, Eli Lilly, Genentech, Genmab, GlaxoSmithKline, Janssen, LOXO, miRNA, Pfizer, Philips, SITC, and Takeda. DSH declares roles as a consultant, speaker, or advisor for Alpha Insights, Acuta, Amgen, Axiom, Adaptimmune, Baxter, Bayer, Boxer Capital, COG, Ecor1, Genentech, GLG, Group H, Guidepoint, HCW Precision, Infinity, Janssen, Merrimack, Medscape, Numab, Pfizer, Prime Oncology, Seattle Genetics, ST Cube, Takeda, Tavistock, Trieza Therapeutics, and WebMD. DSH. has other ownership interests with Molecular Match (Advisor), OncoResponse (Founder) and Presagia (Advisor).

  • Provenance and peer review Not commissioned; externally peer reviewed.